Ikena oncology inc IKNA.US 總覽分析
IKNA 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
IKNA 近期報酬表現
-3.20%
Ikena oncology inc
1.99%
同產業平均
-0.64%
S&P500
與 IKNA 同產業的標的表現
- BCAX Bicara therapeutics inc價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
IKNA 公司資訊
Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595's ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.